: Senesco Technologies, Inc. FD Bruce Galton Brian Ritchie Chief Executive Officer (brian.ritchie@fd.com) (bgalton@senesco.com) (212) 850-5600 (732) 296-8400 SENESCO ANNOUNCES

SENESCO ANNOUNCES RESULTS OF PRE-CLINICAL

TOXICOLOGY AND DOSE RANGING STUDIES FOR MULTIPLE MYELOMA

THERAPEUTIC CANDIDATE

BRUNSWICK, N.J. February 3, 2009 Senesco Technologies, Inc. ( Senesco

or the Company ) (NYSE Alternext US: SNT) today announced

results of efficacy, toxicological and dose-finding studies in mice for its

potential multiple myeloma drug candidate, SNS-01. SNS-01 is a nano-encapsulated combination

therapy of Factor5A and an siRNA against Factor 5A. These studies, undertaken to determine the efficacy,

maximum tolerated dose and the feasibility of long-term intravenous

administration of SNS-01, were performed at the University of Waterloo,

The Company s anti-myeloma efficacy study in severe combined immune-deficient

mice with human multiple myeloma subcutaneous tumors tested SNS-01 dosages

ranging from 0.15 mg/kg to 1.5 mg/kg. In

these studies, mice treated with a dose of either 0.75 mg/kg or 1.5 mg/kg both

showed a 91% reduction in tumor volume and a decrease in tumor weight of 87%

and 95%, respectively. For mice that

received smaller doses of either 0.38 mg/kg or 0.15 mg/kg, there was also a

reduction in tumor volume (73% and 61%, respectively) and weight (74% and 36%,

respectively). All of the treated mice,

regardless of dose, survived.

This therapeutic dose range provided the basis for an 8 day maximum

tolerated dose study in which normal mice received two intravenous doses of

increasing amounts of SNS-01 (from 2.2 mg/kg to 3.7 mg/kg). Body weight, organ weight and serum levels of

liver enzymes were used as clinical indices to assess toxicity. A dose between 2.2 mg/kg and 2.9 mg/kg was

well tolerated with respect to these clinical indices, and the survival rate at

2.9 mg/kg was 80%. Those mice receiving

above 2.9mg/kg of SNS-01 showed evidence of morbidity and up to 80%

mortality. The 2.9 mg/kg threshold,

twice the upper end of the therapeutic dose range, was therefore determined to

be the maximum tolerated dose in mice.

The final study, a 9-week repeated dose study in normal mice, was

designed to assess toxicity following long-term administration of twice-weekly

therapeutic doses (1.5 mg/kg) of SNS-01.

This study also included a group of mice that were dosed with a

mouse-specific eIF5A siRNA to determine whether there were any toxic effects of

suppressing eIF5A in mouse tissues. The change in mean body weight of the

treated and untreated mice was exactly the same over the course of the

study. In addition to the indices studied

in the maximum tolerated dose experiment, hematology was monitored in this

experiment. Over the course of six

weeks, both the mean red blood cell count (9.8 for control mice, 9.6 for

treated mice) and white blood cell count (7.5 for control mice, 7.2 for treated

mice) remained consistent, further supporting the conclusion that SNS-01 was

non-toxic in these studies. Histopathological analysis of the major organs was

conducted by an independent pathologist and revealed no toxicity attributable

Richard Dondero, Senesco s Vice President of Research and Development

commented, These mouse efficacy studies allowed us to determine a proposed

therapeutic dose range for SNS-01. The results of our pre-clinical toxicology

and dose-ranging studies indicate a maximum tolerated dose 2-4 times higher

than those producing anti-tumor effects in mice.

It is Senesco s goal to file an Investigational New Drug Application

for SNS-01 before the end of calendar year 2009. The Company will need to conduct longitudinal

toxicology studies and meet with the FDA during this process.

Senesco s SNS-01 consists of three components: an eIF5A plasmid, an

siRNA against eIF5A and polyethyleneiminie (PEI). The eIF5A plasmid upregulates the apoptotic

pathways within cancer cells. The siRNA

downregulates proinflammatory cytokines, NF-kB and ICAM, which are

proliferation factors for multiple myeloma.

PEI is a nanoparticle complexed to the other two components for

intravenous delivery.

Senesco Technologies, Inc.

Technologies, Inc. is a U.S. biotechnology company, headquartered in New

Brunswick, NJ. Senesco has initiated preclinical research to trigger or delay

cell death in mammals (apoptosis) to determine if the technology is applicable

in human medicine. Accelerating apoptosis may have applications to development

of cancer treatments. Delaying apoptosis may have applications to certain

diseases inflammatory and ischemic diseases. Senesco takes its name from the

scientific term for the aging of plant cells: senescence. Delaying cell breakdown

in plants extends freshness after harvesting, while increasing crop yields,

plant size and resistance to environmental stress. The Company believes that

its technology can be used to develop superior strains of crops without any

modification other than delaying natural plant senescence. Senesco has

partnered with leading-edge companies engaged in agricultural biotechnology and

earns research and development fees for applying its gene-regulating platform

technology to enhance its partners products.

statements included in this press release are forward-looking statements within

the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from

such statements expressed or implied herein as a result of a variety of

factors, including, but not limited to: the development of the Company s gene

technology; the approval of the Company s patent applications; the

implementation of the Company s research and development programs and joint

ventures; the success of the Company s license agreements; the acceptance by

the market of the Company s products; success of the Company s preliminary

studies and preclinical research; competition and the timing of projects and

trends in future operating performance, our ability to maintain our continued

listing standards for the next 12 months, as well as other factors expressed

from time to time in the Company s periodic filings with the Securities and

Exchange Commission (the SEC ). As a result, this press release should be read

in conjunction with the Company s periodic filings with the SEC. The forward-looking statements contained

herein are made only as of the date of this press release, and the Company

undertakes no obligation to publicly update such forward-looking statements to

reflect subsequent events or circumstances.